Skip to main content

Advertisement

SpringerLink
Log in

Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients

  • Research Article
  • Published:
Tumor Biology

Abstract

The excision repair cross-complementation group 1 (ERCC1) plays an essential role in DNA repair and has been linked to resistance to platinum-based anticancer drugs among advanced non-small cell lung cancer (NSCLC) patients. We systematically evaluate whether ERCC1 Asn118Asn and C8092A genetic variants are associated with treatment response of platinum chemotherapy. We preformed a meta-analysis using ten eligible cohort studies (including 11 datasets) with a total of 1,252 NSCLC patients to summarize the existing data on the association between the ERCC1 Asn118Asn and C8092A polymorphisms and response to platinum regiments. Odds ratio or hazard ratio with 95% confidence interval were calculated to estimate the correlation. We found that neither ERCC1 C8092A polymorphism nor Asn118Asn variant is associated with different response of platinum-based treatment among advanced NSCLC patients. Additionally, these two genetic variants are not related to treatment response in either Caucasian patients or Asian patients. Our meta-analysis indicates that the ERCC1 Asn118Asn and C8092A polymorphisms may not be good prognostic biomarkers for platinum-based chemotherapy in patients with stage III–IV NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gandara D, Narayan S, Lara Jr PN, Goldberg Z, Davies A, Lau DH, et al. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005;11(13 Pt 2):5057s–62s.

    Article  PubMed  CAS  Google Scholar 

  2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350(4):379–92.

    Article  PubMed  CAS  Google Scholar 

  3. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1(1):22–33.

    Article  PubMed  CAS  Google Scholar 

  4. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366–74.

    Article  PubMed  CAS  Google Scholar 

  5. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24(5):331–44.

    Article  PubMed  CAS  Google Scholar 

  6. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307–20.

    Article  PubMed  CAS  Google Scholar 

  7. de Laat WL, Appeldoorn E, Jaspers NG, Hoeijmakers JH. DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem. 1998;273(14):7835–42.

    Article  PubMed  Google Scholar 

  8. Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei YF, Moggs JG, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell. 1996;86(5):811–22.

    Article  PubMed  CAS  Google Scholar 

  9. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med. 2004;14(6):959–70.

    PubMed  CAS  Google Scholar 

  10. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin Cancer Res. 2002;8(7):2286–91.

    PubMed  CAS  Google Scholar 

  11. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998;16(1):309–16.

    PubMed  CAS  Google Scholar 

  12. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–91.

    Article  PubMed  CAS  Google Scholar 

  13. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1and ERCC1in lung cancer. N Engl J Med. 2007;356(8):800–8.

    Article  PubMed  CAS  Google Scholar 

  14. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15(8):1194–203.

    Article  PubMed  CAS  Google Scholar 

  15. Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Zhang XR, et al. Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy. Ai Zheng. 2005;24(12):1510–3.

    PubMed  CAS  Google Scholar 

  16. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2011;28(1):315–21.

    Article  PubMed  CAS  Google Scholar 

  17. Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health. 2010;213(2):140–5.

    Article  PubMed  CAS  Google Scholar 

  18. Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol. 2010;33(5):489–94.

    Article  PubMed  CAS  Google Scholar 

  19. Kimcurran V, Zhou C, Schmid-Bindert G, Shengxiang R, Zhou S, Zhang L, et al. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Adv Med Sci. 2011;56:30–8.

    Article  PubMed  CAS  Google Scholar 

  20. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10(2):118–23.

    Article  PubMed  CAS  Google Scholar 

  21. Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007;56(2):281–8.

    Article  PubMed  Google Scholar 

  22. Wang J, Zhang Q, Zhang H, Wang Q, Yang X, Gu Y, et al. Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy. Zhongguo Fei Ai Za Zhi. 2010;13(4):337–41.

    PubMed  CAS  Google Scholar 

  23. Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol. 2010;40(10):954–60.

    Article  PubMed  Google Scholar 

  24. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797–803.

    Article  PubMed  CAS  Google Scholar 

  25. HuGE Literature Finder. Available at URL: http://hugenavigator.net/HuGENavigator/startPagePubLit.do.

  26. US National Library of Medicine, National Institutes of Health. PubMed home page. Available at URL: http://preview.ncbi.nlm.nih.gov/pubmed.

  27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.

    PubMed  CAS  Google Scholar 

  28. Petitti DB. Of babies and bathwater. Am J Epidemiol. 1994;140(9):779–82.

    PubMed  CAS  Google Scholar 

  29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

    Article  PubMed  CAS  Google Scholar 

  30. Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res. 2008;14(9):2878–86.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by Beijing Nova Program (no. 2010B013 to M. Yang), the Fundamental Research Funds for the Central Universities (no. ZZ1234 to M. Yang) and National Natural Science Foundation of China (no. 30872968).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Dianke Yu

  2. College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China

    Juan Shi, Li Liu, Xiaojiao Zhang, Chao Lu, Xiaohu Tang, Meng Li, Lingchen Xiao, Zhouwei Zhang, Qipeng Yuan & Ming Yang

  3. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

    Tong Sun

  4. Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Xiaoli Du

  5. College of Life Science and Technology, Beijing University of Chemical Technology, P. O. Box 53, Beijing, 100029, China

    Qipeng Yuan & Ming Yang

Authors
  1. Dianke Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoli Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaojiao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaohu Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Meng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lingchen Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Zhouwei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Qipeng Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ming Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Qipeng Yuan or Ming Yang.

Additional information

Dianke Yu and Juan Shi contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

Treatment characteristics and genotyping methods of studies included in the meta-analysis (PDF 30 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, D., Shi, J., Sun, T. et al. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumor Biol. 33, 877–884 (2012). https://doi.org/10.1007/s13277-011-0314-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-011-0314-y

Keywords

Search

Navigation